



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
August 7, 2018

Therapeutic Class	Drug Name	DURB Recommendations
Fluoroquinolones		
	<i>Baxdela (Intravenous) Injection</i>	NP/PA
	<i>Baxdela (Oral) Tablet</i>	NP/PA
HIV/AIDS		
	<i>Biktarvy (Oral) Tablet</i>	P
Hypoglycemics, Incretin Mimetics/Enhancers		
	<i>Ozempic (Subcutaneous) Injection</i>	NP/PA
Hyperparathyroid Agents		
	<i>Parsabiv (Intravenous) Injection</i>	P/PA (for coverage on the PADL)
Hypoglycemics, SGLT2 Inhibitors		
	<i>Steglatro (Oral) Tablet</i>	NP/PA
Cystic Fibrosis		
	<i>Symdeko (Oral) Tablet</i>	P/PA

P=preferred; NP=non-preferred; PA=prior authorization; PADL=Providers' Administered Drug List